TriSalus Life Sciences announces executive departure

WESTMINSTER, CO - TriSalus Life Sciences, Inc. (NASDAQ:TLSI), a medical device company specializing in surgical and medical instruments with impressive gross profit margins of 87%, has announced the departure of Sean Murphy, an officer and employee of the company. As per the company’s recent 8-K filing with the Securities and Exchange Commission, Murphy will step down from his executive role effective February 28, 2025. However, he will maintain his position on the company’s Board of Directors.

Murphy’s decision to leave his operational duties was reported on February 19, 2025, with the formal notification to the SEC made today. The filing did not specify the reasons for Murphy’s departure from his executive duties, nor did it mention a successor or any interim arrangements that may be in place following his exit.

The company’s stock, which is traded on the Nasdaq Global Market under the symbol TLSI, and its warrants, under the symbol TLSIW, could see investor reaction to this news. However, the impact of Murphy’s departure on the company’s operations and stock performance remains to be observed.

TriSalus Life Sciences, previously known as MedTech Acquisition Corp before a name change on September 30, 2020, is incorporated in Delaware and headquartered in Westminster, Colorado. The company operates within the industrial classification of surgical and medical instruments and apparatus.

This corporate update is based on a press release statement from TriSalus Life Sciences, Inc. and provides the latest available information regarding the company’s executive team. Investors and stakeholders are advised to follow official company announcements for further details and developments.

In other recent news, TriSalus Life Sciences Inc. reported a significant 59% increase in annual revenue for 2024, reaching approximately $29.4 million. This growth was largely attributed to the performance of the company’s TriNav® Infusion System. The company also noted a substantial improvement in operating cash flow for the fourth quarter, alongside projections of over 50% revenue growth for 2025. TriSalus expects to achieve positive EBITDA for the full year and aims to become cash flow positive in the latter half of 2025. Meanwhile, Lake Street Capital Markets initiated coverage of TriSalus with a Buy rating and a $10 price target, citing the company’s strong gross margins and growth potential. In governance updates, TriSalus expanded its Board of Directors by appointing William J. Valle and Dr. Gary B. Gordon, both bringing extensive experience in medical devices and oncology drug development. Additionally, the company announced a reshuffle in its executive leadership team, appointing James Young as Chief Financial Officer, Dr. Richard Marshak as Chief Commercial Officer, and Jodi Devlin as Chief of Clinical Strategy and Operations. These changes are part of TriSalus’s strategic efforts to enhance its leadership and operational capabilities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.